With $120m, HI-Bio Aims To Rapidly Prove Approach To Immune-Mediated Diseases
Phase Ib/IIa Trials To Read Out Next Year
Executive Summary
Human Immunology Biosciences (HI-Bio) launched with $120m and two candidates from MorphoSys, including the CD38 inhibitor felzartamab already in the clinic for immune-mediated kidney diseases.
You may also be interested in...
Finance Watch: Three New Funds Bring $1.6bn-Plus For Biopharma Firms Globally
Private Company Edition: TCGX raises $1bn for its second fund, Goldman Sachs’ first fund totals $650m and Panlin’s biopharma fund grows. Also, Apollo’s series C increases to $260m, Avistone closes a $140m series B, OnCusp raises a $100m series A and HI-Bio grabs $95m in series B cash.
HI Bio Reaches For The Lead With Phase II Primary Membranous Nephropathy Data
While Roche is in Phase III with Gazyva, HI-Bio thinks its autoantibody-depleting mechanism may be the best approach in PMN.
Deal Watch: OrsoBio Reveals Its Metabolic Health Focus With Four Licensing Pacts
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.